
    
      This is a Phase 3, multicenter, randomized, double-blinded, placebo-controlled study to
      assess the efficacy, safety, and immunogenicity of RSVpreF or placebo (1:1 randomization) in
      infants born to healthy women vaccinated during pregnancy, as well as the safety and
      immunogenicity in the pregnant women. This will be a global study which will span multiple
      RSV seasons.
    
  